Abstract
During the last decade we have witnessed substantial improvements in the therapeutic options for pulmonary arterial hypertension (PAH), including true innovations targeting some of the mechanisms involved in the pathogenesis of this devastating disease. Intravenous epoprostenol was the first drug to improve symptoms and survival of patients with PAH. Novel prostanoids, including subcutaneous treprostinil and inhaled iloprost, also have beneficial effects in many patients, although their long-term efficacy is less well known. Among the newer treatments for PAH, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors have reshaped clinical practice. The endothelin receptor antagonist bosentan has been approved in many parts of the world and most current guidelines recommend this drug as first-line treatment for patients with PAH in functional class III. Novel endothelin receptor antagonists such as sitaxsentan sodium and ambrisentan are currently being investigated. The PDE5 sildenafil is also being intensively studied in patients with pulmonary hypertension, and most of the available data look promising, although approval for PAH is still pending. Other PDE5 inhibitors have not yet undergone extensive study in PAH. The increasing insight into the pathogenesis of PAH opens several new therapeutic opportunities, which include vasoactive intestinal peptide, selective serotonin reuptake inhibitors, adrenomedullin and HMG-CoA reductase inhibitors (statins). However, PAH is a complex disorder and targeting a single pathway can not be expected to be uniformly successful. Thus, combining substances with different modes of action is expected to improve symptoms, haemodynamics and survival in PAH patients, although combination therapy has yet to undergo the scrutiny of large randomised clinical trials.
Similar content being viewed by others
References
Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982 Mar 11; 306(10): 557–64
Galie N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004 Jun 16; 43 (12 Suppl.): S81–8
Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43 (12 Suppl.): S48–55
Hoeper MM, Galie N, Simonneau G, et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165(9): 1209–16
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351(14): 1425–36
Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S13–24
Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S5–S12
Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336(2): 111–7
Rubin LJ, Galie N. Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol 2004; 43 (12 Suppl.): S89–90
Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004 Jul; 126 (1 Suppl.): 7S–10S
Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S40–7
Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S56–61
Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (1 Suppl.): 35S–62S
Klepetko W, Mayer E, Sandoval J, et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S73–80
Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S25–32
Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004; 43 (12 Suppl.): S33–9
Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345(20): 1465–72
Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23(4): 637–48
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334(5): 296–302
Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600–7
Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134(1): 44–54
Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004 Dec; 25(24): 2243–78
Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580–7
Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2): 76–81
Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension: German PPH Study Group. J Am Coll Cardiol 2000 Jan; 35(1): 176–82
Sitbon O, Humbert M, Ioos V. Who benefits from long-term calcium channel blocker therapy for primary pulmonary hypertension? [abstract]. Am J Respir Crit Care Med 2003; 167: A440
Woodmansey PA, O’Toole L, Channer KS, et al. Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension. Heart 1996; 75(2): 171–3
Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002 Aug 21; 40(4): 780–8
Higenbottam TW, Butt AY, Dinh-Xaun AT, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998; 79(2): 175–9
Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80(2): 151–5
Humbert M. Improving survival in pulmonary arterial hypertension. Eur Respir J 2005 Feb; 25(2): 218–20
Hoeper MM, Dinh-Xuan AT. Combination therapy for pulmonary arterial hypertension: still more questions than answers. Eur Respir J 2004 Sep; 24(3): 339–40
Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327(2): 70–5
Tuder RM, Cool CD, Gearci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925–32
Higenbottam T, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; I(8385): 1046–7
Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982 Aug; 66(2): 334–8
Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132(6): 425–34
Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002; 26(2): 194–201
Hoeper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and in rat lungs via cAMP. Am J Respir Cell Mol Biol 1997; 17: 748–56
Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995; 48(5): 890–6
McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106(12): 1477–82
Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1995–6
Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13(6): 1351–6
Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs 1992; 43(6): 889–924
Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124(9): 820–4
Olschewski H, Rohde B, Behr J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003; 124(4): 1294–304
Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347(5): 322–9
Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. German PPH Study Group. Ann Intern Med 2000 Mar 21; 132(6): 435–43
Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000 Jun 22; 342(25): 1866–70
Machherndl S, Kneussl M, Baumgartner H, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 2001; 17: 8–13
Schenk P, Petkov V, Madl C, et al. Aerosolized iloprost therapy could not replace long-term iv epoprostenol (prostacyclin) administration in severe pulmonary hypertension. Chest 2001; 119: 296–300
Chattaraj SC. Treprostinil sodium: Pharmacia. Curr Opin Investig Drugs 2002 Apr; 3(4): 582–6
Budev MM, Minai OA, Arroliga AC. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension. Drugs Today (Barc) 2004 Mar; 40(3): 225–34
McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 41(2): 293–9
Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165(6): 800–4
Vachiery JL, Hill N, Zwicke D, et al. Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121(5): 1561–5
Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002; 20(4): 1037–49
Okano Y, Yoshioka T, Shimouchi A, et al. Orally active prostacyclin analogue in primary pulmonary hypertension [letter; published erratum appears in Lancet 1997 Nov 8; 350 (9088): 1406]. Lancet 1997; 349(9062): 1365
Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34(4): 1188–92
Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39(9): 1496–502
Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41(12): 2119–25
Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993 Jun 17; 328(24): 1732–9
Galie N, Grigioni F, Bacchi-Reggiani L. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension [abstract]. Eur J Clin Invest 1996; 26(273): A48
Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120(5): 1562–9
Chen YF, Oparil S. Endothelin and pulmonary hypertension. J Cardiovasc Pharmacol 2000; 35 (4 Suppl. 2): S49–53
Chen YF, Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 2000 Oct; 320(4): 223–32
Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434–40
Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165(3): 398–405
Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002 Mar 5; 105(9): 1034–6
Prakash A, Perry CM. Bosentan. Am J Cardiovasc Drugs 2002; 2(5): 335–43
Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002; 11(7): 991–1002
Weber C, Banken L, Birnboeck H, et al. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39(8): 847–54
Murphey LM, Hood EH. Bosentan and warfarin interaction. Ann Pharmacother 2003; 37(7): 1028–31
Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001 Oct 6; 358(9288): 1119–23
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(12): 896–903
Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41(8): 1380–6
McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005 Feb; 25(2): 244–9
Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169(4): 441–7. Epub 2003 Nov 20
Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997 May 23; 40(11): 1690–7
Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-a receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121(6): 1860–8
Billman GE. Ambrisentan (Myogen). Curr Opin Investig Drugs 2002; 3(10): 1483–6
Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995 Oct; 75(4): 725–48
Ahn HS, Foster M, Cable M, et al. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 1991; 308: 191–7
Cheitlin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease: technology and practice executive committee. Circulation 1999; 99: 168–77
Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84(2): E4
Bharani A, Mathew V, Sahu A, et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 2003 Jan–Feb; 55(1): 55–9
Karatza AA, Narang I, Rosenthal M, et al. Treatment of primary pulmonary hypertension with oral sildenafil. Respiration 2004 Mar–Apr; 71(2): 192–4
Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 2002 Jul–Aug; 54(4): 404–9
Laupland KB, Helmersen D, Zygun DA, et al. Sildenafil treatment of primary pulmonary hypertension. Can Respir J 2003 Jan–Feb; 10(1): 48–50
Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105(20): 2398–403
Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003 Oct 28; 108(17): 2066–9. Epub 2003 Oct 20
Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 2004; 25(5): 431–6
Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension [letter]. N Engl J Med 2000; 343: 1342
Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43(7): 1149–53
Sastry BK, Narasimhan C, Reddy NK, et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 2002 Jul–Aug; 54(4): 410–4
Zimmermann AT, Calvert AF, Veitch EM. Sildenafil improves right-ventricular parameters and quality of life in primary pulmonary hypertension. Intern Med J 2002 Aug; 32(8): 424–6
Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136(7): 515–22
Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42(1): 158–64
Jimenez Lopez-Guarch C, Escribano Subias P, Tello de Meneses R, et al. Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin: long-term results. Rev Esp Cardiol 2004; 57(10): 946–51
Kuhn KP, Wickersham NE, Robbins IM, et al. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp Lung Res 2004; 30(2): 135–45
Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123(4): 1293–5
Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001 Sep 11; 104(11): 1218–22
Palmieri EA, Affuso F, Fazio S, et al. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004 Dec 2; 141(9): 743–4
Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004 Oct 6; 44(7): 1488–96
Granton JT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin 2002 Aug; 20(3): 441–57, vii
Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858–65
McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130: 740–3
Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003 Feb 15; 167(4): 580–6
Christensen DD, McConnell ME, Book WM, et al. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 2004 Jul 15; 94(2): 261–3
Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363(9419): 1461–8
Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30(3): 641–8
Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63(4): 604–6
Makisalo H, Koivusalo A, Vakkuri A, et al. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004 Jul; 10(7): 945–50
Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005 Mar; 25(3): 502–8
Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension: a case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155(3): 990–5
Pellicelli AM, Palmieri F, Cicalini S, et al. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci 2001; 946: 82–94
Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38(8): 1178–85. Epub 2004 Apr 1
Speich R, Jenni R, Opravil M, et al. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly 2001 Dec 1; 131(45–46): 663–5
Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162: 1846–50
Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003 May 15; 167(10): 1433–9
Cea-Calvo L, Escribano Subias P, Tello De Menesses R, et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol 2003; 56(4): 421–5
Sitbon O, Gressin V, Speich R, et al. Bosentan for human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004 Dec 1; 170(11): 1212–7. Epub 2004 Aug 18
Alp S, Schlottmann R, Bauer TT, et al. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. AIDS 2003 Jul 25; 17(11): 1714–5
Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964–73
Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004 Jul; 183(1): 65–70
Resten A, Maitre S, Humbert M, et al. Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. Radiology 2002; 222(3): 782–8
Dufour B, Maitre S, Humbert M, et al. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998; 171(5): 1321–4
Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113(1): 237–40
Humbert M, Maitre S, Capron F, et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1681–5
Gugnani MK, Pierson C, Vanderheide R, et al. Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: a case of pulmonary capillary hemangiomatosis. Arthritis Rheum 2000; 43: 699–703
Davis LL, deBoisblanc BP, Glynn CE, et al. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. Chest 1995; 108(6): 1754–6
Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111(9): 1339–46
Nagaya N, Kyotani S, Uematsu M, et al. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004 Jan 27; 109(3): 351–6
Upton PD, Wharton J, Davie N, et al. Differential adrenomedullin release and endothelin receptor expression in distinct sub-populations of human airway smooth-muscle cells. Am J Respir Cell Mol Biol 2001; 25(3): 316–25
Upton PD, Wharton J, Coppock H, et al. Adrenomedullin expression and growth inhibitory effects in distinct pulmonary artery smooth muscle cell subpopulations. Am J Respir Cell Mol Biol 2001; 24(2): 170–8
Nagaya N, Nishikimi T, Uematsu M, et al. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart 2000; 84(6): 653–8
Nagaya N, Miyatake K, Kyotani S, et al. Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension. Hypertens Res 2003; 26 Suppl.: S141–6
Kandier MA, Von Der Hardt K, Mahfoud S, et al. Pilot intervention: aerosolized adrenomedullin reduces pulmonary hypertension. J Pharmacol Exp Ther 2003 Sep; 306(3): 1021–6. Epub 2003 May 15
Westphal M, Booke M, Dinh-Xuan AT. Adrenomedullin: a smart road from pheochromocytoma to treatment of pulmonary hypertension. Eur Respir J 2004 Oct; 24(4): 518–20
Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002 Nov 15; 166(10): 1403–8. Epub 2002 Aug 15
Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003 Sep; 285(3): H938–45. Epub 2003 May 15
Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003 Sep 30; 108(13): 1640–5. Epub 2003 Sep 8
Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99(3): 249–54
Eddahibi S, Adnot S, Frisdal E, et al. Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J Pharmacol Exp Ther 2001 Apr; 297(1): 148–54
Baumann MH, Ayestas MA, Dersch CM, et al. Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity. Ann N Y Acad Sci 2000; 914: 172–86
Belohlavkova S, Simak J, Kokesova A, et al. Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels. J Appl Physiol 2001 Aug; 91(2): 755–61
Rothman RB, Ayestas MA, Dersch CM, et al. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 1999 Aug 24; 100(8): 869–75
Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108(8): 1141–50
Eddahibi S, Chaouat A, Morrell N, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108(15): 1839–44
Marcos E, Adnot S, Pham MH, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003 Aug 15; 168(4): 487–93. Epub 2003 May 28
Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004 Sep; 24(3): 353–9
Hoeper MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22(2): 330–4
Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004 Dec; 24(6): 1007–10
Acknowledgements
No sources of funding were used in the preparation of this manuscript. Dr Hoeper has received speaker fees from Actelion Pharmaceuticals (manufacturer of bosentan), Schering (manufacturer of iloprost in Europe) and Pfizer (manufacturer of sildenafil). He has received consultant fees from CoTherix (distributor of iloprost in the US) and is a member of an international medical advisory board for Actelion Pharmaceuticals.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoeper, M.M. Drug Treatment of Pulmonary Arterial Hypertension. Drugs 65, 1337–1354 (2005). https://doi.org/10.2165/00003495-200565100-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200565100-00003